Bacterial infections continue to pose a major threat to global health, particularly in the era of increasing antimicrobial resistance.
Carbohydrate-based vaccines targeting bacterial surface polysaccharides have demonstrated success in preventing diseases caused by pathogens such as Streptococcus pneumoniae, Haemophilus influenzae type b, and Neisseria meningitidis.
However, vaccine development remains hindered by challenges including carbohydrate antigen acquisition, epitope identification, conjugation efficiency, immunogenicity optimization, and quality control.
MICROBIOLOGY NEWS: Register with The Microbiologist for more free articles
To address these challenges, an international team of researchers from China and Germany proposed the concept of carbohydrate-based vaccine engineering (CVE) — which integrates the entire vaccine development process into a unified engineering framework — in a review published in Glycoscience & Therapy.
Evolution of carbohydrate vaccines
The researchers examined the evolution of carbohydrate vaccines from first-generation polysaccharide vaccines to glycoconjugate, glycoengineered, synthetic, and hybrid glycoconjugate vaccines. They further highlighted recent advances in chemical and enzymatic glycan synthesis, glycan microarrays, STD-NMR-based epitope mapping, conjugation technologies, vaccine formulation strategies, and clinical translation.
“By viewing vaccine development as a continuous and interconnected process rather than a collection of isolated steps, the aim of is to accelerate the discovery and industrialization of next-generation glycoconjugate vaccines and strengthen global preparedness against emerging bacterial threats,” says corresponding author Jian Yin.
Novelty: The review introduces CVE as a comprehensive conceptual framework that systematically integrates all critical stages of carbohydrate vaccine development. Unlike previous reviews that focus on individual technologies or vaccine types, CVE connects carbohydrate antigen production, glycoepitope mapping, conjugation chemistry, formulation, preclinical evaluation, clinical development, and regulatory approval into a unified engineering paradigm.
The framework also proposes a new perspective on the technological evolution of carbohydrate vaccines by classifying them into five generations: polysaccharide vaccines, glycoconjugate vaccines, glycoengineered vaccines, synthetic glycoconjugate vaccines, and hybrid glycoconjugate vaccines. “By combining emerging technologies such as automated glycan assembly, chemoenzymatic synthesis, glycan microarrays, and artificial intelligence-driven glycoscience, CVE provides a roadmap for transforming carbohydrate vaccine development from empirical discovery toward rational and programmable design,” says Yin.
Way forward
The CVE framework has implications for both vaccine research and public health. “As antimicrobial resistance continues to rise worldwide, effective vaccination represents one of the most sustainable strategies for preventing bacterial infections and reducing antibiotic dependence,” says Yin. “By providing a holistic view of vaccine development, CVE facilitates the identification of bottlenecks, promotes interdisciplinary collaboration, and supports the efficient translation of laboratory discoveries into clinically relevant vaccine products.”
MICROBIOLOGY ON TAP: Get full access to all The Microbiologist articles from just £2.17 a month
Furthermore, advances highlighted within the CVE framework-including synthetic glycan production, AI-assisted antigen design, precise glycoepitope identification, and next-generation glycoconjugate technologies-are expected to enable the development of safer, more effective, and broadly protective vaccines. “Ultimately, CVE establishes a strategic foundation for accelerating innovation in carbohydrate vaccine research and for addressing current and future infectious disease challenges on a global scale,” adds Yin.
No comments yet